Thera-SAbDab

ADALIMUMAB

>   Structural Summary
TherapeuticAdalimumab
TargetTNFA
Heavy ChainEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
100% seqID Fv Structure4nyl [Fvs: AB, CD, EF, HL], 6cr1 [Fvs: HL]
99% seqID Fv Structure3wd5 [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Adalimumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
adalimumab E V Q L V E S G G G L V Q P G R S L R L S C A A S G F T F D D Y A M H W V R Q A P G K G L E W V S A I T W N S G H I D Y A D S V E G R F T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C A K V S Y L S T A S S L D Y W G Q G T L V T V S S
3wd5 E V Q L V E S G G G L V Q P G R S L R L S C A A S G F T F D D Y A M H W V R Q A P G K G L E W V S A I T W N S G H I D Y A D S V E G R F T I S R D N A K N S L Y L D M N S L R A E D T A V Y Y C A K V S Y L S T A S S L D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
adalimumab D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G I R N Y L A W Y Q Q K P G K A P K L L I Y A A S T L Q S G V P S R F S G S G S G T D F T L T I S S L Q P E D V A T Y Y C Q R Y N R A P Y T F G Q G T K V E I K
3wd5 D I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G I R N Y L A W Y Q Q K P G K A P K L L I Y A A S T L Q S G V P S R F S G S G S G T D F T L T I S S L Q P E D V A T Y Y C Q R Y N R A P Y T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (January '23)Approved
Estimated Status (January '23)Active
Recorded Developmental TechnologyCAT Phage Display
INN Year Proposed1999
INN Year Recommended2000
Companies InvolvedAbbvie, MedImmune, 180 Life Sciences
Conditions ApprovedAnkylosing spondylitis, Behcet's syndrome, Crohn's disease, Hidradenitis suppurativa, Juvenile rheumatoid arthritis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis, Rheumatoid arthritis, Spondylarthritis, Ulcerative colitis, Uveitis, Pyoderma
Conditions ActiveDupuytren's contracture, Cognition disorders, Frozen shoulder, Non-alcoholic steatohepatitis
Conditions DiscontinuedInterstitial cystitis
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy